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ABSTRACT
Objectives A previously identified signal transduction
and activator of transcription-3 (STAT3) target-enriched
gene signature in circulating CD4+ T cells of patients
with early rheumatoid arthritis (RA) was prominent in
autoantibody-negative individuals. Here, interleukin
(IL)-6-mediated STAT signalling was investigated in
circulating lymphocytes of an independent early arthritis
patient cohort, seeking further insight into RA
pathogenesis and biomarkers of potential clinical utility.
Methods Constitutive and IL-6-induced expression of
phosphorylated STAT1 (pSTAT1) and pSTAT3 was
determined in T and B cells using Phosflow cytometric
analysis in patients with RA and controls. Contemporaneous
levels of serum cytokines were measured by immunoassay.
Induced gene expression was measured in cultured CD4+T
cells by quantitative real-time PCR.
Results Among circulating lymphocytes of 187 patients
with early arthritis, constitutive pSTAT3 correlated with serum
IL-6 levels maximally in CD4+ T cells. Increased constitutive
pSTAT3, but not pSTAT1, was observed in circulating CD4+
T cells of patients with early anticitrullinated peptide
autoantibody (ACPA)-negative RA compared with disease
controls, and these levels decreased alongside markers of
disease activity with IL-6R-targeted treatment. Among
patients presenting with seronegative undifferentiated
arthritis (UA) the ratio of constitutive pSTAT3:pSTAT1 in
CD4+ T cells contributed substantially to an algorithm for
predicting progression to classifiable RA during a median of
20 months follow-up (area under receiver operator
characteristic curve=0.84; p<0.001).
Conclusions Our findings support a particular role for
IL-6-driven CD4+ T cell activation via STAT3 during the
induction of RA, particularly as a feature of ACPA-negative
disease. CD4+ T cell pSTAT measurements show promise as
biomarkers of UA–RA progression and now require
independent validation.
INTRODUCTION
Anti-citrullinated peptide autoantibody (ACPA)-nega-
tive undifferentiated arthritis (UA) remains a unique
diagnostic challenge in the early arthritis (EA)
clinic.1We previously identified a gene expression ‘sig-
nature’ in circulating CD4+ T cells of EA clinic atten-
dees, which was most prominent in patients with
ACPA-seronegative rheumatoid arthritis (RA), and pre-
dicted UA–RA progression.2 In that work, signal trans-
ducer and activator of transcription (STAT)3-regulated
genes were over-represented in the signature’s
make-up, their expression correlating with paired
serum interleukin (IL)-6 concentrations independently
of C reactive protein (CRP) and tumour necrosis factor
(TNF).2 Similar patterns were not seen for other serum
mediators that signal via STAT3. The importance of
IL-6-mediated STAT3 signalling among CD4+ T cells
during the induction of experimental arthritis, and in
established human RA, has been independently high-
lighted,3 4 and the therapeutic efficacy of IL-6 receptor
(IL-6R) blockade in RA management emphasises the
pathway’s importance in disease pathogenesis.5–8
However, the cellular mechanisms by which IL-6
drives the induction and perpetuation of human
disease remain to be resolved.
IL-6 shares with other gp130-related cytokines
its reliance for signal transduction on the ubiqui-
tously expressed, membrane-bound β-receptor
subunit gp130, but must also bind to its α-subunit
IL-6R (CD126) in either membrane or soluble
form (classical or trans signalling, respectively).9–11
Although downstream signalling occurs primarily
via STAT3, STAT1 is also used,12 and cross-
regulation between these pathways appears to be an
important determinant of cellular responses to
gp130-related cytokines.13 14
The aims of the current study were to validate
our initial observations in an independent EA
patient cohort and to develop a more tractable
assay to facilitate replication by other research
groups. In so doing, we sought a better understand-
ing of IL-6 signalling in lymphocytes as an early
pathological event in the natural history of RA,
compared with other arthritides.
METHODS
Subjects
Biological material was obtained from consecutive,
consenting patients referred from primary care
with recent onset arthritis and recruited from the
Newcastle Early Arthritis Clinic (NEAC), UK,
during 2012–2013. Patients had not been exposed
to disease-modifying antirheumatic drugs or corti-
costeroids. In this cohort, a working clinical diag-
nosis was assigned by a rheumatologist at the first
consultation as previously described,2 with RA
being diagnosed with reference to 2010 European
League Against Rheumatism/American College of
Rheumatology classification criteria.15 Diagnoses
Open Access
Scan to access more
free content
466 Anderson AE, et al. Ann Rheum Dis 2016;75:466–473. doi:10.1136/annrheumdis-2014-205850
Basic and translational research
group.bmj.com on January 27, 2016 - Published by http://ard.bmj.com/Downloaded from 
were validated or, in the case of UA, updated at follow-up visits
over a median period of 20 months (range 13–25). Patients with
established RA treated with the anti-IL-6R monoclonal antibody
tocilizumab16 were recruited from the Freeman Hospital
Musculoskeletal Unit. Additional patients with RA (similarly ful-
filling 2010 classification criteria) and healthy volunteers were
recruited from the Princess Alexandra Hospital and community,
respectively, in Brisbane, Australia. They received a combination
of methotrexate, sulfasalazine and hydroxychloroquine, unless
contraindicated, immediately after diagnosis of RA. Treatment
was intensified according to a response-driven step-up
algorithm.17
All subjects gave written informed consent before inclusion
into the study, which was approved by local ethics committees
at the respective institutions. Patients with pre-existing rhemato-
logical diagnoses, and all those aged <16 years, were excluded.
The disease activity score in 28 joints (DAS28; erythrocyte sedi-
mentation rate, ESR) was used throughout the study to deter-
mine RA disease activity.
Multiparameter flow cytometric analysis of whole blood
The following antibodies were used for Phosflow and IL-6R
phenotype analysis in samples processed at Newcastle:
anti-CD3-Pacific Blue (UCHT1), anti-CD19-FITC (4G7),
anti-CD19-APC (HIB19), anti-Stat3 (pY705)-Alexa Fluor 647
(4/P-STAT3) and anti-Stat1 (pY701)-Alexa Fluor 647 (4a; all
BD Biosciences, Oxford, UK); anti-CD4-APC-eFluor 780 (SK3;
eBioscience, Hatfield, UK); IL-6R-Fluorescein (17506; R&D
Systems Europe, Abingdon, UK). Phosflow was performed on
whole blood, which was either left unstimulated or stimulated
with 100 ng/mL IL-6 (PeproTech EC, London, UK) for 15 min
at 37°C. BD Phosflow Lyse/Fix and BD Phosflow Perm Buffer
III (both BD Biosciences) were used as per the manufacturers’
instructions. IL-6R expression was assessed in whole blood
using BD FACS Lysing Solution (BD Biosciences) as per the
manufacturers’ instructions. Data were collected on a BD
FACSCanto II (BD Biosciences) and analysed using FlowJo
(Treestar, Ashland, Oregon, USA). The protocol followed for
samples processed in Brisbane was similar, using
anti-CD3-Pacific blue (UCHT1), and anti-Stat3 (pY705)-PE
(4/P-STAT3; BD Biosciences), with a Gallios flow cytometer and
Kaluza software for data acquisition/analysis (both Beckman
Coulter). Flow-Set Pro Fluorospheres (Beckman Coulter) were
used to normalise median fluorescence intensities (MFI) for
pSTAT3 measurements between data sets.
Serum cytokine measurement
Between 09:30 and 12:30, baseline serum was drawn and
frozen at −80°C until use. Serum IL-6, TNF and soluble IL-6R
(sIL-6R) were measured using a highly sensitive, validated elec-
trochemiluminescence immunosorbance detection system (Meso
Scale Discovery, Gaithersberg, Massachusetts, USA) as
described.2 Soluble gp130 (sgp130) and IL-23 measurements
were made using a Quantikine ELISA kit (R&D systems,
Minneapolis, Michigan, USA). Manufacturer guidance was
adhered to, but a cocktail of non-human sera (Heteroblock,
Bozeman, Missouri, USA) was added to each assay at an opti-
mised final concentration of 32 mg/mL to correct for potential
assay interference by heterophilic antibodies present in sera.18
Gene expression assays in cultured CD4+ T cells
High-purity CD4+ T cell isolation from whole blood of healthy
volunteers, cell culture in the presence of IL-6/sIL-6R, RNA
extraction and quantitative real-time PCR for measurement of
STAT3 target gene expression were performed as previously
described.2 Raw gene expression data were normalised relative
to the housekeeping gene 18S as 2−ΔCt values to determine fold
induction.
Calculation of Leiden Prediction Score
Using a range of readily available clinical and serological para-
meters, the Leiden Prediction Score1 19 20 was developed to
stratify individuals’ risk of UA–RA progression with reference to
the 1987 RA classification criteria,21 but its value for the same
purpose when applying the 2010 criteria is diminished.22 In the
absence of a validated alternative prediction tool for this setting,
we devised a modification to the algorithm described by its
authors,19 23 incorporating pSTAT1 and pSTAT3 parameters as
outlined in the text and using methodology outlined in the
online supplementary text: ‘Prediction Rule’.
Statistical analyses
The majority of analyses were carried out using SPSS (Chicago,
Illinois, USA), with statistical significance defined by α=5%.
Non-parametric analyses of variance (Kruskal–Wallis test;
Dunn’s posthoc pairwise analyses) and Mann–Whitney U tests
were used for multiple-group and two-group independent com-
parisons, respectively, and Wilcoxon matched pairs test for
paired comparisons. Spearman’s rank correlations and analyses
of covariance were performed for bivariate comparisons; for
multiple or logistic regression dependent variables were selected
as indicated in the text, and skewed data were log10 trans-
formed. Additional receiver operator characteristic (ROC) ana-
lyses, including paired area under curve (AUC) comparisons by
DeLong’s non-parametric method24 and bootstrap cross-
validation (1000 bootstrap samples), were conducted using the
pROC statistical package25 (http://cran.r-project.org). Diagnostic
evaluations were calculated from contingency tables using http://
statpages.org.
RESULTS
Patient groups
A total of 187 NEAC attendees were recruited into the study.
Among this cohort, definitive diagnoses could be assigned by
rheumatologists at first consultation for 152 individuals (81%).
This number increased to 184 (98%) during follow-up.
Diagnoses were further categorised as RA (ACPA positive or
negative), non-RA inflammatory arthritis (non-RA IA) or
non-IA/arthralgia (NIA), as previously described,2 and clinical
characteristics of this cohort are described in table 1. (The same
data stratified by baseline diagnosis is provided in the online
supplementary table S1). The non-RA IA group comprised
psoriatic arthritis (36%), reactive or self-limiting IA (22%),
other spondyloarthropathy including ankylosing spondylitis
(11%), crystal arthropathy (18%) or other IA (13%).
Twenty-seven (40%) of the NIA group were diagnosed with
probable osteoarthritis. A total of 22 additional patients with
RA and 13 healthy controls were recruited from Brisbane, con-
tributing only to experiments presented in figure 1E, F; their
clinical details are provided in the online supplementary table
S2. Details of tocilizumab-treated patients are given in the
online supplementary table S3.
IL-6-mediated STAT3 phosphorylation induces RA ‘signature
genes’ in CD4+ T cells in vitro and is a potential biomarker
The measurement of gene expression in peripheral blood
subsets used in our previous investigation2 is technically challen-
ging, and we therefore sought a more tractable tool for clinical
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application. Whole blood flow cytometric analysis presented a
promising solution. We first confirmed that IL-6-mediated acti-
vation of primary CD4+ T cells could, via STAT3 phosphoryl-
ation, induce the same genes that featured prominently in our
transcriptional signature. Maximal STAT3 phosphorylation was
observed 15 min after IL-6 exposure (figure 1A), and upregula-
tion of its exemplar targets SOCS3, BCL3 and SBNO2 reached
significance at 1 h (figure 1B–D). We next confirmed that detect-
able differences in pSTAT3 were present between distinct
patient populations. We measured constitutive pSTAT3 in
circulating T cells (CD3+) of patients with early untreated RA,
patients with treated RA and healthy volunteers (see online
supplementary table S2A). Significantly higher CD3+ pSTAT3
expression was seen in patients with early RA compared with
both healthy controls and patients with treated RA (figure 1E).
Consistent with this, CD3+ T cell pSTAT3 measurements in
prospectively followed patients with early RA treated with
disease-modifying antirheumatic drugs (DMARDs) diminished
over time (figure 1F; see online supplementary table S2B for
additional clinical detail).
Table 1 Newcastle early arthritis clinic patients stratified by diagnostic outcome at the end of follow-up
ACPA−RA (n=29) ACPA+RA (n=25)
Non-RA inflam.
(n=59)
OA/non-inflam.
(n=71) UA (n=3)
p Value (inflam.
diagnoses*)
p Value
(all diagnoses†)
Age (years) 61 (30 to 88) 58 (27 to 81) 51 (18 to 91) 51 (27 to 86) 45 (24 to 68) 0.01 <0.01
Female, % 69 64 66 72 67 ns ns
Symptom
duration
(weeks)
12 (4 to >52) 16 (4 to >52) 9 (2 to >52) 18 (3 to >52) 24 (6 to 38) ns ns
ESR (seconds) 23 (1 to 71) 21 (4 to 86) 15 (1 to 113) 8 (1 to 100) 21 (20 to 29) ns 0.01
CRP (g/L) 11 (<5 to 91) 10 (<5 to 66) 8 (<5 to 189) <5 (<5 to 49) 12 (6 to 23) ns 0.01
ACPA+, % 0 100 4 0 9 <0.01 <0.01
RF+, % 31 80 5 7 33 <0.01 <0.01
DAS28 4.8 (2.31 to 7.16) 5.00 (1.59 to 7.07) n/a n/a n/a ns –
Except where indicated, median and range are given.
*Kruskal–Wallis ANOVA analysis confined to three groups with confirmed inflammatory diagnoses at inception: ACPA−RA, ACPA+RA and non-RA inflammatory arthritis.
†Kruskal–Wallis ANOVA, five groups, including OA/non-inflammatory arthralgia and UA.
ACPA, anticitrullinated peptide autoantibody; ANOVA, analysis of variance; CRP, C reactive protein DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate;
OA, osteoarthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; UA, undifferentiated arthritis.
Figure 1 (A–D) CD4+ T cells isolated from whole blood of eight healthy volunteers were cultured with 50 ng/mL final concentration recombinant
interleukin (IL)-6 and an equimolar concentration of soluble IL-6 receptor (sIL-6R). Intracellular phosphorylated signal transduction and activator of
transcription-3 (pSTAT3) expression was measured by flow cytometric analysis from one aliquot (A), with induced expression of early rheumatoid
arthritis (RA) ‘signature’ STAT3 target genes SOCS3, BCL3 and SBNO2 being measured in another aliquot for each individual (B–D); preliminary work
established that peak expression was reached at 15 and 60 min, depicted here for pSTAT and transcripts, respectively. (E) pSTAT3 was measured in
circulating CD3+T cells of patients with early RA, established RA counterparts and healthy donors as described; additional clinical information
supplied in the online supplementary table S1. (F) Constitutive CD3+ T cell pSTAT3 was measured serially in 11 newly diagnosed patients with RA
before (pre) and 2–4 months (median 12 weeks) post initiation of disease-modifying antirheumatic drug therapy. Wilcoxon signed-rank test (A–D
and F) or non-parametric analysis of variance with Dunn’s posthoc pairwise analyses (E): *p<0.05, **p <0.01 and ***p<0.001. Error bars indicate
interquartile ranges. MFI, median fluorescence intensity.
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Strong and independent association between circulating
CD4+ T cell pSTAT3 and paired serum IL-6 in EA
Constitutive pSTAT1, pSTAT3 and IL-6R expression in lympho-
cyte subsets was measured alongside paired serum IL-6, IL-6R
and sgp130 concentrations in 187 NEAC patients (all diagnoses;
table 1). Constitutive pSTAT3 expression was highest in CD4+
T cells (figure 2A). A similar pattern was seen for pSTAT1
(figure 2B). Constitutive pSTAT3 correlated with paired serum
IL-6 levels most strongly in CD4+ T cells (r=0.60) and, to a
lesser extent, CD8+ T cells (r=0.36), but not B cells (figure 2C;
also online supplementary figure S1A–C). The relationship was
similar irrespective of diagnostic category (figure 2D; online
supplementary figure S1D–E). Importantly, multiple regression
analysis (using CD4+ T cell pSTAT3 as the independent vari-
able) indicated that the association with IL-6 remained after cor-
rection for age, CRP and circulating of TNF, which does not
signal primarily via STAT3 (β=0.44; p<0.001; online
supplementary table S4), providing strong evidence for a causal
relationship between IL-6 and STAT3 activation. No such corre-
lations were seen in respect of pSTAT1 in any lymphocyte
subset (figure 2E; online supplementary figure S1F–H). As was
the case with IL-10 in our previous study,2 IL-23 (also known to
signal via STAT3) was undetectable in all but a small number of
NEAC patients’ sera (<10%; detection threshold 39 pg/mL; not
shown) and did not correlate with pSTAT3. These results
indicate that, in EA, CD4+ T lymphocytes are most sensitive to
circulating IL-6. No correlation was seen between pSTAT1/3 in
any subset and either circulating IL-6R or sgp130 (see online
supplementary figure S2), excluding an overt influence of these
mediators of trans IL-6 signalling on STAT activation in circulat-
ing lymphocytes. Moreover, strikingly higher levels of mem-
brane IL-6R expression were expressed by circulating CD4+ T
cells than by CD8+ T cells or CD19+ B cells (figure 2F).
Reduction in constitutive CD4+ pSTAT3 after anti-IL-6R
blockade mirrors RA disease activity
To confirm the in vivo role of IL-6 signalling in STAT3 activa-
tion in RA, CD4+ T cell pSTAT3 was monitored in four
patients with established, active RA in whom tocilizumab
therapy was initiated. Clinical characteristics of the patients are
provided in the online supplementary table S3. All four patients
responded clinically to tocilizumab, and we observed that per-
ipheral blood CD4+ T cell pSTAT3 declined with treatment
(figure 3A) in a manner that more closely resembled serial
disease activity scores (DAS28; figure 3B) than did a cruder
measure of response, such as CRP (figure 3C). These data
provide direct in vivo evidence that IL-6-mediated CD4+ T cell
STAT3 activation is associated with disease activity.
Furthermore, pSTAT3 measurement may have value as a bio-
marker for monitoring disease activity in RA.
Figure 2 (A) Constitutive phosphorylated signal transduction and activator of transcription-3 (pSTAT3) expression is maximal in CD4+ T cells
compared with CD8+ and CD19+ cells in the peripheral blood of patients with early arthritis, and (B) a similar pattern is seen for pSTAT1. (C)
Relationship between constitutive pSTAT3 and paired serum interleukin (IL)-6 is strongest in the CD4+ T cell lymphocyte population; significant
differences are seen between best-fit line slopes (analyses of covariance (ANCOVA) p<0.001). (D) Comparable strength of association between
constitutive pSTAT3 in CD4+ T cells and paired circulating IL-6 levels in patients with early rheumatoid arthritis (RA; black) and a disease control
group comprising non-RA inflammatory arthritis (grey); no difference in the slope of the best-fit lines is seen between the comparator groups
(ANCOVA). (E) Serum IL-6 does not correlate with basal pSTAT1 in any lymphocyte subset. (F) Surface IL-6R expression is maximal in the CD4+ T
lymphocyte subset. ***p<0.001, non-parametric analysis of variance with Dunn’s posthoc pairwise analyses; Spearman correlation coefficients (rho)
and associated p values are depicted. Correlation plots are also presented individually in the online supplementary figure S1, for further clarity. MFI,
median fluorescence intensity.
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Constitutive and induced CD4+ T cell pSTAT3 discriminates
early ACPA-negative RA, reflecting serum IL-6 levels
Constitutive and IL-6-induced pSTAT1 and pSTAT3 expression was
measured in lymphocytes of 184 EA clinic attendees, stratified by
diagnostic category. Neither pSTAT1 nor pSTAT3 differed between
diagnostic groups among CD8+ T cells or CD19+ B cells
(see online supplementary figure S3A–D). In CD4+ T cells, basal
pSTAT3 was significantly higher in patients with ACPA-negative RA
than in non-RA IA and NIA controls (figure 4A,B; the same pattern
was observed when patients with RA were stratified according to
whether they were seronegative for both rheumatoid factor and
ACPA; online supplementary figure S3E). The expected reciprocal
pattern was seen with respect to induced pSTAT3 in CD4+ T cells
on ex vivo IL-6 stimulation of whole blood (figure 4A, C; online
supplementary figure S3F), reflecting reduced STAT3 phosphoryl-
ation capacity in vitro where constitutive pSTAT3 is increased. The
relationship between serum IL-6 concentration and diagnostic cat-
egory mirrored that of CD4+ Tcell pSTAT3, being highest among
patients with ACPA-negative RA (median 8.6 pg/mL; figure 4D).
No differences were seen in constitutive CD4+ T cell pSTAT1
between diagnostic outcome groups (see online supplementary
figure S4). Given the relatively high surface expression of IL-6R by
CD4+ T cells (figure 2F), we investigated whether differential
expression of this receptor according to diagnostic category could
explain the observed differences in CD4+ Tcell pSTAT3 levels, but
found this not to be the case (figure 4E). Neither sIL-6R nor
sgp130 differed between patients grouped according to diagnostic
category (see online supplementary figure S5). These results indicate
that IL-6 drives STAT3 phosphorylation prominently (and in prefer-
ence to STAT1 phosphorylation) in circulating CD4+ T lympho-
cytes of patients with early ACPA-negative RA.
Constitutive CD4+ T cell pSTAT measurement has predictive
value in diagnosing UA
We explored the potential of CD4+ T cell pSTAT3 as a diagnos-
tic biomarker for EA patients with unclassifiable disease. Among
32 of 35 such patients with UA for whom outcome diagnoses
became available, 12 had evolved to classifiable RA over a
median of 20-months follow-up, compared with the remaining
20 assigned alternative (non-RA) diagnoses. Despite equivalent
baseline clinical parameters (including inflammatory markers;
online supplementary table S5) and circulating IL-6 levels (figure
5A), pSTAT3 in total CD4+ Tcells differed significantly between
the two outcome groups at baseline, being highest in UA–RA
patients (p=0.02; figure 5B). Although no difference was seen
between the two groups in respect of CD4+ T cell pSTAT1 or
surface IL-6R expression (see online supplementary figure S6),
the ratio of constitutive CD4+ T cell pSTAT3 to pSTAT1
([MFIpSTAT3]/[MFIpSTAT1]) was again found to be highest in the
UA–RA group (p=0.008; figure 5C).
The use of revised RA classification criteria15 has diminished
the prevalence of ACPA in early UA,26 and this was reflected in
our small cohort, all but one of whom were ACPA negative (see
online supplementary table S5). The Leiden prediction rule,
developed for use prior to this revision in classification, assigns
a heavy predictive weighting to ACPA-positive individuals with
respect to progression from UA to RA.1 19 Therefore, we rea-
soned that substitution of the prediction rule’s ACPA compo-
nent with an indicator of constitutive CD4+ STAT3/1 signalling
might enhance its utility for predicting ACPA-seronegative UA–
RA progression under 2010 classification criteria. Indeed, the
predictive power of the published Leiden rule for an RA
outcome in our small patient group was modest (AUC 0.67,
95% CI 0.47 to 0.87; figure 5D), consistent with previous
reports.1 2 22 By comparison, the predictive power of constitu-
tive CD4+ T cell pSTAT3 (MFI; AUC=0.77, 95% CI 0.61 to
0.95) or, as depicted in figure 5D, the pSTAT3:pSTAT1 ratio
(AUC 0.78; 95% CI 0.61 to 0.95) appeared greater, although
differences were not significant (p=0.4).
Maximal predictive utility for RAwas achieved when the Leiden
rule was modified to incorporate pSTAT3:pSTAT1 in place of
ACPA status (see online supplementary text: ‘Prediction Rule’;
AUC 0.84; 95% CI 0.68 to 1.0). This was significantly enhanced
over that of the Leiden score alone (p=0.04; figure 5D). To
address a potential over-fitting issue, a bootstrap cross-validation
approach was also performed and gave similar AUC values, indi-
cating that they are unlikely to be grossly inflated (see online
supplementary table S6). An optimum cut-off value for the com-
posite metric of 9.5 for determining likely progression of UA to
RA had positive and negative predictive values of 0.82 (95% CI
0.54 to 0.96) and 0.86 (0.71 to 0.93), respectively (see also online
supplementary table S7).
DISCUSSION
We report the first detailed, prospective analysis of IL-6 pathway
activation parameters in a well-characterised EA patient cohort.
Of particular clinical relevance, we find that measurement of the
constitutive pSTAT3:pSTAT1 ratio in CD4+ T cells by flow
cytometry holds promise as a predictive biomarker for RA pro-
gression among newly presenting ACPA-negative UA patients.
Moreover, its incorporation into a prediction algorithm for
evolving RA, itself published prior to revised classification cri-
teria, yields a potentially valuable tool for predicting UA–RA
progression in the post-2010 era. Our finding warrants replica-
tion in diverse EA cohorts as a priority. Importantly, our new
Figure 3 Longitudinal analysis of total CD4+ phosphorylated signal transduction and activator of transcription-3 (pSTAT3) (A), disease activity
score in 28 joints (DAS28) (B) and C reactive protein (CRP; C) in four patients with established rheumatoid arthritis. Measurements were made
immediately before, and 1 month after, initial treatments with tocilizumab. Additional clinical information is available in the online supplementary
table S4. MFI, median fluorescence intensity.
470 Anderson AE, et al. Ann Rheum Dis 2016;75:466–473. doi:10.1136/annrheumdis-2014-205850
Basic and translational research
group.bmj.com on January 27, 2016 - Published by http://ard.bmj.com/Downloaded from 
data confirm the importance of IL-6-mediated CD4+ T cell
STAT3 signalling in early RA2 and highlight flow cytometry as a
method by which IL-6/STAT3 pathway activation might be used
as a diagnostic biomarker. With this in mind, the use of the
pSTAT3:pSTAT1 ratio was preferred over pSTAT3 MFI alone,
representing a metric that can be more easily standardised for
use between laboratories and technologies.
The activation of STAT3 by IL-6 in circulating CD4+ T cells
raises intriguing questions as to the pathway’s role in RA induc-
tion. Our observation that cytokine-mediated T cell activation
accompanies the earliest clinical phase of RA recalls previous
evidence that such mechanisms might underpin disease patho-
genesis independently of antigen recognition.27 28 An IA mouse
model characterised by mutated IL-6 signalling machinery has
recently added support to this concept.29–31 We noted that per-
ipheral blood CD4+ T cells from patients with untreated RA
and non-RA IA were similarly ‘sensitive’ to circulating IL-6
(figure 2D) excluding differential cytokine responsiveness as the
driver of distinctive cellular STAT3 phosphorylation between
disease phenotypes. However, CD4+ pSTAT3 (together with
the pSTAT3:pSTAT1 ratio) appears to be a more accurate pre-
dictor of ACPA-negative RA than IL-6 before the disease is fully
clinically manifest (figure 5), potentially incriminating factors
other than IL-6 that affect the STAT3 pathway (such as
membrane-bound gp130 expression, which we did not measure
in our study). Understanding such processes within the clinical
context of early RA will inform efforts to refine targeted RA
treatments of the future.32 33
Despite being carefully planned and conducted over a 2-year
period, our study was limited by relatively few patients with UA.
Considering this alongside the heterogeneity of EA, this affected
statistical power. Moreover, it is conceivable that the utility of
our putative biomarker is critically dependent on one or other
of the technical parameter(s) that were carefully controlled at
our unit—including (but not limited to) the UA definition, non-
exposure to DMARDs among participants, the time of blood
draw or the decision to stain fresh blood (eg, rather than frozen
peripheral blood mononuclear cells). Replication of our findings
will therefore be the final arbiter of both their validity and their
clinical utility.
Key questions raised by our work include the cellular source
of excess IL-6 in incipient RA, its influence on downstream
effector CD4+ T cell function and the relative contribution of
classical versus trans IL-6 signalling to the process. Of further
interest will be the extent to which these steps are regulated by
genetic determinants.34 35 Finally, the apparent dominance of
IL-6-driven CD4+ T cell STAT3 activation in ACPA-negative,
over ACPA-positive, RA deserves attention (figure 4B,D). In
fact, our data overall suggest that IL-6-driven STAT3 activation
is relevant to the pathogenesis of both serotypes, but its relative
importance in ACPA-negative disease may be greater. Other
mechanisms (including the production of autoantibodies
Figure 4 (A) Representative flow cytometry histograms depicting basal and interleukin (IL)-6-induced phosphorylated signal transduction and
activator of transcription-3 (pSTAT3) in CD4+ T cells from exemplar patient with non-rheumatoid arthritis (non-RA) inflammatory arthritis disease
control (shaded plots) and anticitrullinated peptide autoantibody (ACPA)-negative RA (non-shaded plots); constitutive pSTAT3 is greater in the
patient with ACPA-negative RA (dotted lines depict fluorescence-minus-one control). (B) Constitutive CD4+ T cell pSTAT3 expression differs according
to diagnosis, being significantly higher in ACPA-negative RA than in inflammatory/non-inflammatory control groups. (C) The opposite relationship
with diagnostic outcome is seen in respect of ex vivo IL-6-induced CD4+ T cell pSTAT3 fold induction. (D) Serum IL-6 concentrations differed
according to diagnosis, mirroring CD4+ T cell STAT3 pattern (compare B). (E) Differences in constitutive pSTAT3 between disease phenotypes were
not explained by differential CD4+ T cell membrane expression of IL-6R. *p<0.05, **p<0.01 and ***p<0.001 (Dunn’s posthoc pairwise analysis
following non-parametric analysis of variance); MFI, median fluorescence intensity; OA, osteoarthritis.
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themselves) may play a balancing role in ACPA-positive RA
induction, but further study will be needed to explore this
hypothesis.
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